CVRX

CVRx, Inc.

Nasdaq · Surgical & Medical Instruments & Apparatus · Inc. DE · CIK 0001235912
$5.03 +2.86% $133.5M
Insider Buying Cluster (6 insiders)High Impact Filing (8/10)7 New Institutional Positions3 Institutional Exits
Vol
Market Cap$133.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders42 funds
Inst. Value$52.8M
Inst. Activity7 buys / 3 sells
Insider Activity1B / 5S
Insider Net $$171.0K
SEC Reports11
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001235912·Prev Close $4.89

Recent Activity

Jun 11, 2026 SEC
A bullish institutional cluster formed in CVRX during Q3 2024, with 6 buyers adding $897K in net new holdings versus 2 s
INST-CLUSTER — Impact 4/10
Jun 9, 2026 SEC
CFO Jared Oasheim has resigned to pursue other opportunities, effective upon appointment of a successor. He will remain
8-K — Impact 3/10
Jun 9, 2026 SEC
CVRx reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with revenue of $15.6M in line with estimates.
PRESS-RELEASE — Impact 5/10
Jun 1, 2026 Insider
Nielsen Kirk G. was granted 8,720 shares
Director
Jun 1, 2026 Insider
Jain Mudit K. was granted 11,182 shares
Director
Jun 1, 2026 Insider
Jain Mudit K. was granted 8,720 shares
Director
Inst.
TUDOR INVESTMENT CORP ET — ADD
197,340 shares ($1.9M)
Inst.
MORGAN STANLEY — TRIM
139,364 shares ($1.3M)

Price Targets

$11.17 +122.0% upside Strong Buy
Current $5.03 Low $6.00 Median $12.00 High $14.00 6 analysts
$6.00 $14.00

Analyst Ratings

Strong Buy85% buy · 13 analysts
3Strong Buy
8Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Apr 14, 2026 Canaccord Genuity MAINTAIN Buy → Buy
Feb 13, 2026 Canaccord Genuity MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.52 ▼ -1.1% $-0.57 — $-0.46 8% YoY 7
Next Q $-0.48 ▼ -1.3% $-0.56 — $-0.41 1% YoY 7
Current FY $-1.96 ▲ +0.7% $-2.13 — $-1.74 4% YoY 7
Next FY $-1.89 ▼ -1.4% $-2.17 — $-1.42 3% YoY 7

Latest Reports

BULLISH INST-CLUSTER 4/10
A bullish institutional cluster formed in CVRX during Q3 2024, with 6 buyers adding $897K in net new holdings versus 2 s
Jun 11, 2026
NEUTRAL 8-K 3/10
CFO Jared Oasheim has resigned to pursue other opportunities, effective upon appointment of a successor. He will remain
Jun 9, 2026

Top Institutional Holders

FundValueMove
BlackRock, Inc.$9.7M—
VANGUARD CAPITAL MANAGEMENT LLC$8.6M—
ROYAL BANK OF CANADA$6.7MADD
BALYASNY ASSET MANAGEMENT L.P.$6.0MADD
SILVERCREST ASSET MANAGEMENT GROUP$5.4MADD

Recent Insider Trades

DateInsiderTypeValue
Jun 1, 2026Nielsen KirkA$0.00
Jun 1, 2026Jain MuditA$0.00
Jun 1, 2026Jain MuditA$0.00
Jun 1, 2026Ballinger KevinA$0.00
Jun 1, 2026SHADAN MARTHAA$0.00
42 institutional holders with $52.8M total value (5,594,608 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, ROYAL. Net buying activity: 7 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.1,026,559$9.7M18.4%—
2VANGUARD CAPITAL MANAGEMENT LLC911,310$8.6M16.3%—
3ROYAL BANK OF CANADA706,950$6.7M12.7%ADD +96.0%
4BALYASNY ASSET MANAGEMENT L.P.630,812$6.0M11.3%ADD +65.5%
5SILVERCREST ASSET MANAGEMENT GROUP LLC572,021$5.4M10.3%ADD +76.6%
6STATE STREET CORP350,548$3.3M6.3%—
7GOLDMAN SACHS GROUP INC201,011$1.9M3.6%—
8TUDOR INVESTMENT CORP ET AL197,340$1.9M3.5%ADD +25.5%
9MORGAN STANLEY139,364$1.3M2.5%TRIM -63.4%
10VANGUARD FIDUCIARY TRUST CO127,761$1.2M2.3%—
11TWO SIGMA INVESTMENTS, LP114,167$1.1M2.0%TRIM -30.9%
12Cresset Asset Management, LLC106,349$1.0M1.9%ADD +48.1%
13VANGUARD PORTFOLIO MANAGEMENT LLC94,849$897.3K1.7%—
14DIMENSIONAL FUND ADVISORS LP52,641$497.3K0.9%ADD +44.2%
15Nuveen, LLC42,749$404.4K0.8%TRIM -38.9%
16CHARLES SCHWAB INVESTMENT MANAGEMENT INC40,821$386.2K0.7%—
17DEUTSCHE BANK AG\34,157$323.1K0.6%ADD +60.4%
18BANK OF AMERICA CORP /DE/30,969$293.0K0.6%TRIM -30.4%
19CITADEL ADVISORS LLC26,627$251.9K0.5%ADD +40.7%
20RENAISSANCE TECHNOLOGIES LLC19,300$182.6K0.3%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
TUDOR INVESTMENT CORP ET ALADD157,260197,340+25.5%$1.9M2026-Q1
MORGAN STANLEYTRIM380,641139,364-63.4%$1.3M2026-Q1
Cresset Asset Management, LLCADD71,802106,349+48.1%$1.0M2026-Q1
DEUTSCHE BANK AG\ADD21,28934,157+60.4%$323.1K2026-Q1
BANK OF AMERICA CORP /DE/TRIM44,49430,969-30.4%$293.0K2026-Q1
CWM, LLCDOUBLED448,059+18215.9%$76.2K2026-Q1
NISA INVESTMENT ADVISORS, LLCDOUBLED1597,027+4319.5%$66.5K2026-Q1
FMR LLCDOUBLED3012,164+618.9%$20.5K2026-Q1
GROUP ONE TRADING LLCNEAR_EXIT5,426423-92.2%$4.0K2026-Q1
PNC FINANCIAL SERVICES GROUP, INC.DOUBLED512+140.0%$114.002026-Q1
SILVERCREST ASSET MANAGEMENT GROUP LLCADD359,376634,639+76.6%$4.5M2025-Q4
D. E. Shaw & Co., Inc.ADD76,44996,212+25.9%$683.1K2025-Q4
MARSHALL WACE, LLPDOUBLED16,15049,827+208.5%$353.8K2025-Q4
BANK OF AMERICA CORP /DE/NEAR_EXIT180,42544,494-75.3%$315.9K2025-Q4
Nuveen, LLCTRIM69,24942,289-38.9%$300.3K2025-Q4
TWO SIGMA INVESTMENTS, LPTRIM35,39024,456-30.9%$173.6K2025-Q4
DEUTSCHE BANK AG\DOUBLED9,55221,289+122.9%$151.2K2025-Q4
WELLS FARGO & COMPANY/MNADD12,56120,266+61.3%$143.9K2025-Q4
Mitsubishi UFJ Asset Management Co., Ltd.TRIM27,84811,297-59.4%$80.2K2025-Q4
CWM, LLCDOUBLED736+414.3%—2025-Q3
BANK OF AMERICA CORP /DE/DOUBLED89,049180,425+102.6%$1.5M2025-Q3
UBS Group AGADD88,144151,323+71.7%$1.2M2025-Q3
D. E. Shaw & Co., Inc.ADD53,37576,449+43.2%$616.9K2025-Q3
Cresset Asset Management, LLCADD53,54271,802+34.1%$579.4K2025-Q3
Nuveen, LLCADD42,28969,249+63.8%$558.8K2025-Q3
14 unique insiders with 34 transactions. Net insider value: $171.0K ($297.6K bought, $126.6K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 1, 2026Nielsen Kirk G.DirectorAWARD8,720——
Jun 1, 2026Jain Mudit K.DirectorAWARD11,182——
Jun 1, 2026Jain Mudit K.DirectorAWARD8,720——
Jun 1, 2026Ballinger Kevin J.DirectorAWARD11,182——
Jun 1, 2026SHADAN MARTHADirectorAWARD8,720——
Jun 1, 2026Hill, Mitch C.DirectorAWARD11,182——
Jun 1, 2026SLATTERY JOSEPH PDirectorAWARD11,182——
Jun 1, 2026Nielsen Kirk G.DirectorAWARD11,182——
Jun 1, 2026SLATTERY JOSEPH PDirectorAWARD8,720——
Jun 1, 2026DALE MICHAEL DDirectorAWARD36,252——
Jun 1, 2026Ballinger Kevin J.DirectorAWARD8,720——
Jun 1, 2026DALE MICHAEL DDirectorAWARD29,005——
Jun 1, 2026SHADAN MARTHADirectorAWARD11,182——
Jun 1, 2026Hill, Mitch C.DirectorAWARD8,720——
Mar 2, 2026VERRASTRO PAULCHIEF MKTG & STRAT OFFICERSELL1,284$7.90$10.1K
Mar 2, 2026OASHEIM JAREDCHIEF FINANCIAL OFFICERSELL1,744$7.90$13.8K
Mar 2, 2026Morrison GregoryCHIEF HUMAN RESOURCES OFFICERAWARD34,000——
Mar 2, 2026Hykes KevinPRES & CEOSELL7,763$7.90$61.3K
Mar 2, 2026Morrison GregoryCHIEF HUMAN RESOURCES OFFICERAWARD154,500——
Mar 2, 2026Adamson Philip B.Chief Medical OfficerSELL1,262$7.90$10.0K
Mar 2, 2026John Robert AllenChief Revenue OfficerSELL3,964$7.90$31.3K
Feb 27, 2026John Robert AllenChief Revenue OfficerAWARD35,000——
Feb 27, 2026Binkowski BrentCHIEF OPERATING OFFICERAWARD23,000——
Feb 27, 2026VERRASTRO PAULCHIEF MKTG & STRAT OFFICERAWARD45,000——
Feb 27, 2026OASHEIM JAREDCHIEF FINANCIAL OFFICERAWARD61,000——
Feb 27, 2026Binkowski BrentCHIEF OPERATING OFFICERAWARD15,000——
Feb 27, 2026Hykes KevinPRES & CEOAWARD159,000——
Feb 27, 2026Hykes KevinPRES & CEOAWARD238,000——
Feb 27, 2026Adamson Philip B.Chief Medical OfficerAWARD62,000——
Feb 27, 2026Adamson Philip B.Chief Medical OfficerAWARD41,000——
Feb 27, 2026John Robert AllenChief Revenue OfficerAWARD52,000——
Feb 27, 2026VERRASTRO PAULCHIEF MKTG & STRAT OFFICERAWARD67,000——
Feb 27, 2026OASHEIM JAREDCHIEF FINANCIAL OFFICERAWARD91,000——
Feb 20, 2026Jain Mudit K.DirectorBUY46,800$6.36$297.6K
11 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 8 neutral. Avg impact: 3.8/10.
BULLISH INST-CLUSTER 4/10
A bullish institutional cluster formed in CVRX during Q3 2024, with 6 buyers adding $897K in net new
Jun 11, 2026
NEUTRAL 8-K 3/10
CFO Jared Oasheim has resigned to pursue other opportunities, effective upon appointment of a succes
Jun 9, 2026
NEUTRAL PRESS-RELEASE 5/10
CVRx reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with revenue of $15.6M in
Jun 9, 2026
NEUTRAL 3 2/10
Michael D. Dale filed a Form 3 initial statement of beneficial ownership with the SEC, indicating he
Jun 3, 2026
NEUTRAL 8-K 5/10
CVRx reported Q1 2026 revenue of $14.8M (+20% YoY), in line with the preliminary range, and a net lo
May 11, 2026
NEUTRAL PRESS-RELEASE 2/10
CVRx announced it will release Q1 2026 financial results after market close on May 11, 2026, with a
Apr 27, 2026
BULLISH 8-K 8/10
CVRx reported preliminary Q1 2026 revenue of $14.7–14.8 million (approximately 20% YoY growth) and r
Apr 21, 2026
NEUTRAL DEFA14A 2/10
CVRx, Inc. filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. The fi
Apr 20, 2026
NEUTRAL CLUSTER 3/10
Analysis based on filing metadata only — document content was unavailable. The filing indicates an i
Mar 16, 2026
BEARISH CLUSTER 5/10
Multiple C-suite executives at CVRx, including the CEO, CFO, and CRO, conducted open-market share sa
Mar 4, 2026
NEUTRAL CLUSTER 3/10
Three CVRX executives — CFO, CRO, and COO — received non-cash stock awards totaling 111,000 shares,
Mar 3, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 3 strong buy, 8 buy, 1 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$11.17 mean target +122.0% upside Strong Buy (1.57)
$6.00 Low $14.00 High
MetricValue
Current Price$5.03
Target Low$6.00
Target Mean$11.17
Target Median$12.00
Target High$14.00
# Analysts6
RecommendationStrong Buy (1.57)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.52 $-0.57 $-0.46 8.1% -1.1% 4↑ 1↓ $0.0B 14.4% 7
Next Q
2026-09-30
 $-0.48 $-0.56 $-0.41 1.2% -1.3% 2↑ 1↓ $0.0B 14.6% 7
Current FY
2026-12-31
 $-1.96 $-2.13 $-1.74 3.8% +0.7% 5↑ 0↓ $0.1B 15.2% 7
Next FY
2027-12-31
 $-1.89 $-2.17 $-1.42 3.5% -1.4% 1↑ 4↓ $0.1B 16.7% 7

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.524
7d ago$-0.524
30d ago$-0.518-0.006
60d ago$-0.522-0.002
90d ago$-0.522-0.002
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Apr 14, 2026 Canaccord Genuity MAINTAIN Buy Buy
Feb 13, 2026 Canaccord Genuity MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263811085%
May 1, 20263811085%
Apr 1, 20263811085%
Mar 1, 20263811085%
Feb 1, 20263811085%
Jan 1, 20263811085%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 9, 2026
earnings
CVRx Announces Chief Financial Officer Transition
<p>MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developin
May 27, 2026
other
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
<p>MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing
May 20, 2026
other
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
<p>MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing
May 14, 2026
other
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
<p>MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing
May 11, 2026
earnings_calendar
CVRX Q1 2026 Earnings After Market Close — 2026-05-11
May 4, 2026
fda
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
<p align="left">MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturi
Apr 29, 2026
earnings_calendar
CVRX Q1 2026 Earnings After Market Close — 2026-04-29
Apr 27, 2026
earnings
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
<p>MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developi
Apr 20, 2026
routine
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
<p align="left">MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufactu
Mar 2, 2026
routine
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
<p align="left">MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufactu